Chemomab Therapeutics (CMMB)

• Market cap: $11M
• 1 day: -7.77%
• 5 days: -8.25%
• 1 month: 13.38%
• 3 months: -8.25%
• 6 months: -32.32%
• Year to date: -0.56%
• 1 year: -67.04%
• 5 years: -99.04%
• 10 years: -99.74%
• Sector: Healthcare
• Industry: Biotechnology

About: Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Employees: 16